Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,826 across all filing types
Latest filing 2021-06-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the approval of a pharmaceutical product (辛伐他汀片) passing a regulatory quality and efficacy consistency evaluation by the National Medical Products Administration. It details the drug's specifications, market context, and potential impact on the company. The document is relatively short (1477 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement about a regulatory approval related to the company's product, not a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-07 Chinese
哈药集团股份有限公司九届九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details the decision of the company's ninth board meeting to convene the 2020 annual general meeting on June 25, 2021. The text is short (404 characters) and primarily announces a board decision rather than providing detailed financial data or full report content. It does not contain financial statements or comprehensive report information. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-06-03 Chinese
哈药集团股份有限公司关于召开2020年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of 哈药集团股份有限公司, including details such as the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather information about the meeting where such reports will be discussed and voted on. The document length is 3474 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-06-03 Chinese
北京兴华会计师事务所（特殊普通合伙）关于上海证券交易所《关于哈药集团股份有限公司2020年年度报告的信息披露监管问询函》的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm to a regulatory inquiry by the Shanghai Stock Exchange regarding the 2020 annual report of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It discusses accounting treatments, impairment provisions, financial data, and disclosures related to investments and transactions with GNC Holdings Inc. The document includes extensive financial analysis, accounting policy explanations, and audit opinions related to the 2020 fiscal year. The presence of detailed financial data, accounting standards references, and audit opinions indicates this is part of the audit report or audit-related information rather than the full annual report itself. The document is lengthy (15,000 characters) and contains substantive financial and audit content, not merely an announcement or certification. Therefore, the document best fits the category of Audit Report / Information (AR). FY 2020
2021-05-14 Chinese
哈药集团股份有限公司关于对上海证券交易所《关于哈药集团股份有限公司2020年年度报告的信息披露监管问询函》的回复公告
Annual Report Classification · 95% confidence The document is a detailed response from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2020 Annual Report. It discusses in depth the financial performance, product sales, inventory, impairment provisions, and related party transactions, including detailed financial data and accounting treatments related to investments and impairments. The document references the 2020 Annual Report multiple times and provides extensive financial and operational analysis, including auditor opinions. The length of the document (15,000 characters) and the detailed financial content indicate this is not a brief announcement or a certification but a substantive report or part of the annual report disclosures. Therefore, the document should be classified as an Annual Report (10-K equivalent) rather than a Regulatory Filing or Report Publication Announcement. Confidence is high due to the detailed financial data, accounting discussions, and auditor opinions related to the annual period 2020. FY 2020
2021-05-14 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划首次授予结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant results of a 2021 stock option and restricted stock incentive plan by 哈药集团股份有限公司. It details the number of stock options and restricted stocks granted, the recipients, the terms of the incentive plan, performance conditions, and the registration of these grants with the securities registration authority. It also includes information on the impact on the company's shareholding structure and the use of funds raised. The document is a formal announcement of the stock incentive plan grant results and related details, not a full financial report, audit report, or management discussion. It is not a report publication announcement since it contains substantive details and is not merely stating that a report is attached or published elsewhere. The content fits best under the category of Capital/Financing Update (CAP) because it relates to equity incentive plans, issuance of shares to employees, and changes in capital structure due to stock option and restricted stock grants.
2021-05-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.